Services

Formulation of the various cannabinoids for improved local and systemic bioavailability and better performances. We also develop co-formulations of cannabinoids together with other beneficial ingredients.

A trial must be carefully designed. We prepare protocols that answer the clients’ demands in terms of clinical objectives as well as budget & schedule

Pre-clinical in vivo trials are designed to check safety and efficacy for fine-tuning of the final product. These trials provide important information regarding toxicity, tolerability, efficacy, dosing, administration route and regime, etc.

Phase I human clinical trials are targeted to test the safety of the new product, while Phase II human clinical trials also involve efficacy parameters. In order to minimize costs and time, we try to get the maximum from every dollar.

Safety studies in the laboratory, on animals and in humans, are a crucial stage in any product development. Efficacy trials allow us to evaluate new products versus other products available in the marketplace. The tailored combination of the two leads to a shorter and more efficient R&D course, in terms of time & costs.

Nutraceuticals (dietary supplements) are substances that provide medical or health benefits, including the prevention and treatment of disease. Although nutraceuticals are not considered drugs and no scientific claims can be made, the safety and efficacy of the products should be carefully tested in order to provide consumers with a safe and efficient product, usually consumed for long periods.

Bioavailability is a key factor, as it defines how much of the active ingredient will reach the target organ. Low bioavailability will result in low efficacy and is sometimes associated with high toxicity. We deal with both local (specific organs) and systemic (plasma) bioavailability and specific formulations targeted for improved bioavailability.

Without the appropriate regulatory approvals by the regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), a product could not be placed on the market. Regulatory consulting is important from the very early stages in order to assure an appropriate R&D course.

Intellectual Properties (IPs) and patents are real assets, and protecting them is the most important part. We provide an evaluation of IP as a stand-alone service or as a part of a Due Diligence that analyses the current status of the development including regulatory status, IP, market analysis, etc., as well as market potential and future steps to be performed. Our Due Diligence is performed for all types of investors as well as for internal purposes.

Leveraging our extensive network, and long time industry experience in biotech, agritech, and foodtech we are developing strategic partnerships between leading companies and creating new business opportunities to bring to market breakthrough innovations.